# Chidamide With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer

> **NCT02815007** · PHASE2 · UNKNOWN · sponsor: **Yuankai Shi** · enrollment: 20 (estimated)

## Conditions studied

- Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Chidamide with EGFR-TKI

## Key facts

- **NCT ID:** NCT02815007
- **Lead sponsor:** Yuankai Shi
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-06
- **Primary completion:** 2018-03
- **Final completion:** 2018-06
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2016-06-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02815007

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02815007, "Chidamide With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02815007. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*